Literature DB >> 33334453

Catheter Ablation Versus Medication in Atrial Fibrillation and Systolic Dysfunction: Late Outcomes of CAMERA-MRI Study.

Hariharan Sugumar1, Sandeep Prabhu2, Ben Costello3, David Chieng1, Sonia Azzopardi3, Aleksandr Voskoboinik1, Ramanathan Parameswaran4, Geoffrey R Wong4, Robert Anderson5, Ahmed M Al-Kaisey4, Liang-Han Ling6, Emily Kotschet7, Andrew J Taylor3, Jonathan M Kalman5, Peter M Kistler8.   

Abstract

OBJECTIVES: This study sought to determine the long-term outcomes of restoring sinus rhythm with catheter ablation (CA).
BACKGROUND: The CAMERA-MRI (Catheter Ablation Versus Medical Rate Control in Atrial Fibrillation and Heart Failure-An MRI-Guided Multicenter Randomized Controlled Trial) study demonstrated that restoration of sinus rhythm with CA significantly improved left ventricular ejection fraction (LVEF) compared with medical rate control (MRC) at 6 months in persistent atrial fibrillation and otherwise unexplained systolic heart failure. However, the long-term outcomes have not been reported.
METHODS: Patients enrolled in the CAMERA-MRI study were followed for 4 years with echocardiogram and cardiac magnetic resonance. CA involved pulmonary vein isolation and posterior left atrial wall isolation in 94%. Patients crossed over to CA after 6-month study duration. Arrhythmia burden was determined with implanted cardiac monitors or cardiac devices.
RESULTS: Sixty-six patients (age 62 ± 10 years, atrial fibrillation duration of 22 ± 16 months, and LVEF 33 ± 9%) were randomized 1:1 to CA versus MRC. Eighteen of 33 patients crossed over from MRC group to CA group. At 4.0 ± 0.9 years, atrial fibrillation recurred in 27 patients (57%) in the CA group with a mean burden of 10.6 ± 21.2% after 1.4 ± 0.6 procedures. There was an absolute increase in LVEF with CA of 16.4 ± 13.3% compared with 8.6 ± 7.6% in MRC (p = 0.001). In the CA group, the absence of ventricular late gadolinium enhancement was associated with a greater improvement in absolute LVEF (19 ± 13% vs. 10 ± 11% in the late gadolinium enhancement-positive group; p = 0.04) and LVEF normalization in 19 patients (58%) versus 4 patients (18%) in the late gadolinium enhancement-positive group (p = 0.008) at 4.0 ± 0.9 years follow-up.
CONCLUSIONS: CA is superior to MRC in improving LVEF in the long term in patients with atrial fibrillation and systolic heart failure. The greatest recovery in systolic function was demonstrated in the absence of ventricular fibrosis on cardiac magnetic resonance.
Copyright © 2020 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  atrial fibrillation; cardiomyopathy; catheter ablation; long-term outcomes; maintained; reversible

Year:  2020        PMID: 33334453     DOI: 10.1016/j.jacep.2020.08.019

Source DB:  PubMed          Journal:  JACC Clin Electrophysiol        ISSN: 2405-500X


  4 in total

1.  Life-Years Lost After Newly Diagnosed Atrial Fibrillation in Patients with Heart Failure.

Authors:  Nicklas Vinter; Pia Cordsen; Gregory Y H Lip; Emelia J Benjamin; Søren Paaske Johnsen; Lars Frost; Ludovic Trinquart
Journal:  Clin Epidemiol       Date:  2022-05-31       Impact factor: 5.814

Review 2.  Electrical management of heart failure: from pathophysiology to treatment.

Authors:  Frits W Prinzen; Angelo Auricchio; Wilfried Mullens; Cecilia Linde; Jose F Huizar
Journal:  Eur Heart J       Date:  2022-05-21       Impact factor: 35.855

3.  Cryoballoon Ablation for the Treatment of Atrial Fibrillation in Patients With Concomitant Heart Failure and Either Reduced or Preserved Left Ventricular Ejection Fraction: Results From the Cryo AF Global Registry.

Authors:  Roberto Rordorf; Fernando Scazzuso; Kyoung Ryul Julian Chun; Surinder Kaur Khelae; Fred J Kueffer; Kendra M Braegelmann; Ken Okumura; Fawzia Al-Kandari; Young Keun On; Csaba Földesi
Journal:  J Am Heart Assoc       Date:  2021-12-10       Impact factor: 5.501

4.  Catheter Ablation versus Medical Therapy of Atrial Fibrillation in Patients with Heart Failure: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Michele Magnocavallo; Antonio Parlavecchio; Giampaolo Vetta; Carola Gianni; Marco Polselli; Francesco De Vuono; Luigi Pannone; Sanghamitra Mohanty; Filippo Maria Cauti; Rodolfo Caminiti; Vincenzo Miraglia; Cinzia Monaco; Gian-Battista Chierchia; Pietro Rossi; Luigi Di Biase; Stefano Bianchi; Carlo de Asmundis; Andrea Natale; Domenico Giovanni Della Rocca
Journal:  J Clin Med       Date:  2022-09-21       Impact factor: 4.964

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.